NP speak is sometimes hard to decipher. Did he say in the proactive interview today that the FDA was integral in helping the Company to increase the rate of enrollment by stopping eINDs? Couple this with what he said previously about the FDA relaxing conditions for participants to enroll in ph3 SC trials and I come to the conclusion that potential eINDs patients got routed into ph3 trials...which would be as close to an EUA as possible without being one. If this is true, I take back my outrage about how the FDA has put other interests over peoples' lives (w.r.t. C19).